ORAMED PHARMACEUTICALS INC.
ORMP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ORMP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ORMP
Oramed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing an oral delivery platform for therapeutic proteins, including insulin, and has recently restructured its operations through the OraTech transaction.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$205.9M
Cash Runway
408.7 moLead Asset
oral insulin (Preclinical)
Next Catalyst
Phase3_Topline · May 22, 2027Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial · 1 catalyst for ORAMED PHARMACEUTICALS INC..
Oramed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing an oral delivery platform for therapeutic proteins, including insulin, and has recently restructured its operations through the OraTech transaction.
- Oramed has developed an oral dosage form intended to withstand the gastrointestinal tract and deliver active insulin or other proteins without chemical or biological modification [sec_mda · as of 2026-03-26].
- The company has not generated significant revenues from operations other than deferred revenue from license agreements [sec_mda · as of 2026-08-10].
- As of June 30, 2026, Oramed reported cash and equivalents of $15.2M and net income of $78.2M [sec].
- Following the termination of Phase 3 trials (ORA-D-013-1 and ORA-D-013-2), the oral insulin platform development has been transferred to OraTech, and Oramed expects reduced R&D expenses [sec_mda · as of 2026-08-10].
What works
- Oramed's oral delivery platform has the potential to convert injectable therapies (e.g., insulin) into oral formulations, addressing a large unmet need for patient convenience [sec_mda · as of 2026-03-26].
- The company holds strategic investments in healthcare and life sciences companies (e.g., Scilex, Alpha Tau) that may provide financial upside [sec_mda · as of 2025-08-14].
- Oramed has a history of raising capital through securities offerings and warrant exercises, demonstrating some access to funding [sec_mda · as of 2025-08-14].
What to weigh
- Oramed has a history of losses and has not generated significant product revenues; profitability is uncertain [sec_mda · as of 2026-03-26].
- The company's oral insulin program faced setbacks with the termination of two Phase 3 trials (ORA-D-013-1 and ORA-D-013-2) [sec_mda · as of 2026-08-10].
- Future financing may not be available on acceptable terms due to difficult capital market conditions, which could force operational reductions [sec_mda · as of 2026-08-10].
- Clinical trial risks include potential inconsistent results, slow enrollment, and reliance on third-party sites [sec_mda · as of 2026-03-26].
From the filings
Quoted directly from source documents.
Oramed's oral dosage form is designed to deliver proteins without chemical modification.
“The formulation is not intended to modify the proteins chemically or biologically, and the dosage form is designed to be safe to ingest.”
SEC MD&A · March 26, 2026
Oramed has not generated significant revenues from operations.
“From inception through June 30, 2026, we have not generated significant revenues from our operations, other than the recognition of deferred revenue related to the HTIT License Agreement and the Medicox License Agreement”
SEC MD&A · August 10, 2026
The company's Phase 3 trials were terminated and development transferred to OraTech.
“Following the termination of our Phase 3 clinical trials, our research and development activities were significantly reduced while we conducted a strategic review process. Following the closing of the OraTech transaction, the development of the oral insulin platform is conducted by OraTech”
SEC MD&A · August 10, 2026
Oramed may need additional financing and faces capital market risks.
“additional financing may not be available on acceptable terms, if at all, including due to the difficult conditions in the capital markets.”
SEC MD&A · August 10, 2026
Catalyst timeline
- 2027-05-22 · Phase3_Topline — Topline results from a double-blinded, placebo-controlled Phase 3 study evaluating the oral insulin capsule.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Future clinical results may replicate prior Phase 3 failures or be inconsistent with earlier data [sec_mda · as of 2026-03-26].
- Financing and liquidity risk — Oramed may need substantial additional capital; unfavorable market conditions could limit access [sec_mda · as of 2026-08-10].
- Regulatory approval uncertainty — No assurance of FDA or foreign regulatory approval for any product candidate [sec_mda · as of 2026-03-26].
- Dependence on OraTech — Oral insulin development now conducted by OraTech, reducing Oramed's direct control over progress [sec_mda · as of 2026-08-10].
What to watch
- Progress of the revised Phase 3 trial (ORA-D-013-3) being conducted through OraTech [sec_mda · as of 2026-05-19].
- Oramed's ability to secure additional financing given capital market conditions [sec_mda · as of 2026-08-10].
- Value realization from strategic investments in Scilex, Alpha Tau, and others [sec_mda · as of 2025-08-14].
- Any new strategic partnerships or licensing deals for the oral delivery platform [sec_mda · as of 2026-03-26].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run ORAMED PHARMACEUTICALS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ORAMED PHARMACEUTICALS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
408.7 months
OCF -$200K · Net income $78M
Lead: Phase 3
2 candidates
1 upcoming, next in ~265d
0 buys · 2 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
60
Total value held
$23.2M
| Holder | Shares | Value |
|---|---|---|
| aquamarine financial (cayman) ltd | 2,112,312 | $7.2M |
| mercer global advisors inc /adv | 1,910,540 | $6.5M |
| boothbay fund management, llc | 600,716 | $2.0M |
| marshall wace, llp | 259,611 | $883K |
| dimensional fund advisors lp | 158,209 | $538K |
| wells fargo & company/mn | 157,586 | $536K |
| ritholtz wealth management | 155,479 | $529K |
| renaissance technologies llc | 147,700 | $502K |
| bank of america corp /de/ | 146,152 | $497K |
| susquehanna international group, llp | 136,218 | $463K |
Showing top 10 of 60 institutional holders of ORAMED PHARMACEUTICALS INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 1.7%
- Days to cover
- 5.7
- Shares short
- 576,933
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ORMP short interestGovernance
Frequently asked questions
What is the AI investment thesis for ORAMED PHARMACEUTICALS INC.?
Oramed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing an oral delivery platform for therapeutic proteins, including insulin, and has recently restructured its operations through the OraTech transaction.
What is ORAMED PHARMACEUTICALS INC.'s lead drug candidate?
ORAMED PHARMACEUTICALS INC.'s most advanced tracked candidate is oral insulin (Preclinical) for diabetes.
What is ORAMED PHARMACEUTICALS INC.'s next catalyst?
ORAMED PHARMACEUTICALS INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evalua" — expected May 22, 2027.
Who is the CEO of ORAMED PHARMACEUTICALS INC.?
Mr. Nadav Kidron Esq. is the chief executive officer of ORAMED PHARMACEUTICALS INC. (ORMP).
Where is ORAMED PHARMACEUTICALS INC. headquartered?
ORAMED PHARMACEUTICALS INC. (ORMP) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.